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pus, with concomitantly increased activity of insulin-de-
grading enzyme at the age of 6 months. However,  RAGE 
 deletion could neither prevent the decline in cognitive per-
formance nor the age-related cerebral accumulation of A  
peptide. Furthermore, histological analysis revealed no dif-
ference in the microglia-occupied brain areas or microglial 
morphologies between RAGE –/– /arcA  and arcA  mice. 
 Conclusions: Together, our results indicate that while the 
absence of RAGE was associated with increased insulin-de-
grading enzyme activity in the brain, it was not sufficient to 
prevent or ameliorate cognitive deterioration, A  accumu-
lation and microglial activation in the arcA  mouse model 
of AD.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Alzheimer’s disease (AD), the most common form of 
dementia, is characterized by progressive cognitive defi-
cits with underlying amyloid-  peptide (A  ) accumula-
tion, neuronal dysfunction and neuroinflammation. 
Both the evolution of neuronal impairment and inflam-
matory processes in AD pathology are suggested to be a 
result of receptor-mediated interactions with A  . One 
candidate receptor is the receptor for advanced glycation 
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 Abstract 
 Background: Alzheimer’s disease (AD) is characterized by 
brain accumulation of the amyloid-  peptide (A  ) that trig-
gers a cascade of biochemical and cellular alterations result-
ing in the clinical phenotype of the disease. While numer-
ous experiments addressed A  toxicity, the mechanisms are 
still not fully understood. The receptor for advanced glyca-
tion end products (RAGE) binds A  and was suggested to 
be involved in the pathological processes of AD.  Objective: 
Our purpose was to assess the effect of  RAGE deletion on 
A  -related pathology.  Methods: We crossed RAGE knock-
out (RAGE –/– ) mice with transgenic mice harboring both the 
Swedish and Arctic A  precursor protein mutations (arcA  
mice). We assessed A  levels, A  brain deposition, A  -de-
grading enzyme activities, A  precursor protein expression 
and processing, number and morphology of microglia as 
well as cognitive performance of 6- and 12-month-old 
 RAGE –/– /arcA  , RAGE –/– , arcA  and wild-type mice.  Results: 
RAGE –/– /arcA  mice had significantly lower levels of SDS- 
and formic-acid-extracted A  in the cortex and hippocam-
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end products (RAGE), a multiligand receptor belonging 
to the immunoglobulin superfamily  [1] . To determine the 
phenotype of brain   -amyloidosis in the absence of 
RAGE, we developed a mouse model, RAGE –/– /arcA  . 
ArcA  mice, which overexpress the human   -amyloid 
precursor protein (APP) with both the Swedish and the 
Arctic mutations, show first cognitive deficits at the age 
of 6 months  [2] . At that age, the animals have abundant 
A  intracellular punctate deposits in the cortex and hip-
pocampus with no apparent A  plaque load. At 12 months 
of age, A  plaques and cerebral amyloid angiopathy 
(CAA) are prominent features. Therefore, we analyzed 
the RAGE –/– /arcA  mice at 6 and 12 months of age, and 
tested their cognitive abilities, biochemical and histo-
pathological changes, including brain A  levels, plaque 
load, CAA and microglial morphology. RAGE –/– /arcA  
animals showed significantly lower levels of SDS- and 
formic-acid-extractable A  in the cortex and hippocam-
pus presumably related to concomitant increases in insu-
lin-degrading enzyme (IDE) activity, as compared with 
arcA  mice at the age of 6 months. However, these differ-
ences did not result in better cognitive performance and 
were no longer detectable 6 months later when massive 
A  accumulation occurs.
 Materials and Methods 
 Animals 
 RAGE knockout (RAGE –/– ) mice  [3] were crossed with arcA  
mice  [2] to generate the RAGE –/– /arcA  mouse model. The arcA  
model is based on the overexpression of human APP 695 with
the Swedish (K670N/M671L) and the Arctic (E693G) mutations 
in a single construct under the control of the prion protein pro-
moter. There were 4 genotypes investigated in parallel: RAGE –/– /
arcA  mice, their respective RAGE –/– littermates, arcA  and 
their respective wild-type littermates. Six- and 12-month-old 
mice, 8–9 animals per genotype and age, were analyzed. Each 
animal group was balanced for gender. The mice were kept under 
standard housing conditions and a reversed 12-hour light/dark 
cycle, with free access to food and water. The animal experiments 
were approved by the Cantonal Veterinary Authority of Zurich. 
The abrogation of RAGE expression in RAGE –/– animals was 
demonstrated by Western blot of lung tissue, both directly by 
 detecting no RAGE signal and indirectly by demonstrating re-
porter EGFR expression (online supplementary fig. 1, www. 
karger.com/doi/10.1159/000261723).
 Y Maze 
 The spontaneous alternation rate was assessed using a Y-
shaped plastic maze, with 40  ! 20  ! 10 cm arm sizes. During 
5-min sessions, the sequences of arm entries were recorded; alter-
nation was defined as successive entries into 3 arms, in overlap-
ping triplet sets. The percent alternation was calculated as the 
ratio of actual to possible alternations (defined as the total num-
ber of arm entries – 2)  ! 100%. The behavioral testing was per-
formed in the dark phase.
 Tissue Preparation 
 Within 1 week of Y maze testing the mice were anesthetized 
with ketamine-xylazine cocktail (10 mg/kg, i.p.) and flush-per-
fused transcardially with ice-cold phosphate-buffered saline. 
Brains were rapidly removed and divided sagittally. One hemi-
brain was postfixed in phosphate-buffered 4% paraformaldehyde 
and paraffin-embedded; the other hemibrain was dissected into 
cortex, hippocampus and cerebellum snap-frozen and stored at 
–80 ° C for protein analysis.
 Histology 
 Five-micrometer-thick sagittal sections were cut with a Leica 
RM 2135 microtome. The sections were pretreated with citrate 
buffer (20 min in microwave at 85 ° C) followed by 95% formic acid 
(FA) [(5 min at room temperature (RT)], and blocked with 4% bo-
vine serum albumin, 5% goat serum and 5% horse serum at RT 
for 1 h. The sections were subsequently incubated with primary 
antibodies overnight at 4 ° C at the following dilutions: mouse 
6E10 (1: 500); rabbit anti-Iba1 (1: 500). Secondary fluorophore-
conjugated antibodies were used for 2 h at RT. Thioflavin S stain-
ing was done according to standard protocol. Automated plaque 
and microglia counting was performed on 6 sections from each 
animal, spaced 50   m apart, using the software Image J (http://
rsb.info.nih.gov/ij/). The measurements were limited to the cor-
tex, which was analyzed in the frontal and parietal regions, and 
the hippocampus.
 Three-Step A  Extraction Protocol 
 Cortices were homogenized in 10 tissue volumes (w/v) of 1% 
Triton X-100 buffer (50 m M of Tris-HCl, pH 8.0/1% Triton X-100/
complete protease inhibitor cocktail, Roche) with Teflon glass ho-
mogenizer (40 strokes) and subsequently centrifuged at 100,000  g 
for 1 h at 4 ° C. The supernatant was retained as the 1% Triton X-
100 soluble fraction. The resulting pellet was homogenized in 10 
tissue volumes (w/v) of 2% SDS buffer (50 m M of Tris-HCl, pH 
8.0/2% SDS/2 m M EDTA/complete protease inhibitor cocktail 
EDTA-free, Roche) and centrifuged at 100,000  g for 1 h at 8 ° C. 
The ensuing supernatant was collected as the 2% SDS soluble 
 fraction. Given the small amount of tissue obtained per hemi-
brain, mouse hippocampi were homogenized in 10 tissue volumes 
(w/v) of 1% Triton X-100, 2% SDS buffer (50 m M of Tris-HCl, pH 
8.0/1% Triton X-100/2% SDS/complete protease inhibitor cock-
tail, Roche) with Teflon glass homogenizer (40 strokes) and sub-
sequently centrifuged at 100,000  g for 1 h at 8 ° C. Two percent SDS 
pellets from cortices and hippocampi were further extracted with 
a minimum of 225   l of 70% FA and spun at 100,000  g for 1 h at 
8 ° C. The FA supernatant was collected by aspiration, avoiding the 
surface lipid layer and the acid insoluble bottom pellet. Aliquots 
of the 70% FA soluble fraction were lyophilized overnight in order 
to remove the acid and stored at –80 ° C.
 Immunoblots 
 Tissue extracts were separated by SDS-PAGE using 10–20% 
 Tricine gels (Invitrogen) and transferred onto nitrocellulose mem-
branes. After an optional epitope retrieval and blocking in 5% milk 
TBS-T, the membranes were probed with 6E10 (1: 500, Signet), 
22C11 (1: 1,000, Chemicon International), anti-APP C-terminal
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(1: 4,000, Sigma), anti-mouse/rat RAGE (1: 500, R&D Systems;
1: 1,000 rabbit polyclonal antibodies against RAGE V, C1 and C2 
domains  [4] ) and anti-GFP (1: 1,000, Roche) antibodies. Immu-
nopositive bands were visualized by chemiluminescence (ECL, 
Amersham Biosciences) and subsequently quantified by densito-
metric analysis of their intensity levels.   -Tubulin was used as load-
ing control (1: 10,000, Sigma). The results were expressed as signal 
intensities normalized to values pertaining to arcA  animals.
 A  40 and A  42 ELISA of Cerebral A  
 The A  40 and A  42 quantities in the above-mentioned frac-
tions were determined using hAmyloid   40 and hAmyloid   42 
ELISA kits (The Genetics Company AG, Switzerland).
 Enzymatic Assays 
 Cortical tissue from 4 mice per genotype was pooled. The 
pooled tissue was homogenized in a 4-fold (w/v) volume of 20 m M 
Tris-HCl (pH 7.4), 0.5% Triton X-100, 10   M PMSF. Homogenate 
was centrifuged at 13,000 rpm for 15 min at 4 ° C. Supernatant was 
used as a sample for the assay. The protein concentration was de-
termined with the BCA Protein Assay (Pierce) and measured 
against bovine serum albumin standards.
 IDE Activity Assay. The IDE activity in the supernatant was 
determined with the fluorometric Innozyme Insulysin/IDE Im-
munocapture Activity Assay Kit (Calbiochem, Merck) according 
to the manufacturer’s instructions. The reaction time was 1 h. The 
IDE activity was expressed in nanograms/milliliter of crude cor-
tical homogenates that were normalized to 2 mg/ml protein con-
centration.
 Angiotensin-Converting Enzyme Activity Assay.  The angioten-
sin-converting enzyme (ACE) activity in the supernatant against 
the synthetic substrate N-hippuryl- L -histidyl- L -leucine was de-
termined using an ACE colorimetric kit (Buhlmann Laboratories 
AG, Schönenbuch, Switzerland). The reaction time was 3 h.
 Neprilysin Activity Assay. The neprilysin enzyme activity was 
measured as described previously  [5, 6] , using a fluorometric as-
say for the generation of free dansyl-D-Ala-Gly (DAG) from  N -
dansyl-Ala-Gly-D-nitro-Phe-Gly (DAGNPG; Sigma), a fluoro-
genic substrate for neprilysin. Substrate solutions containing
1 m M of DAGPNG and 10   M of enalapril (Sigma) in 20 m M of 
Tris HCl with and without the addition of 10   M of NEP inhibitor 
phosphoramidon were prepared and preincubated at 37 ° C for 10 
min. Enalapril, an ACE inhibitor, was added to prevent ACE-me-
diated DAGNPG cleavage. Fifty micorliters of the sample were 
incubated for 1 h with 100   l of each substrate solution. The reac-
tion was stopped by boiling for 10 min at 90 ° C. The samples were 
then spun for 5 min at 10,000 rpm. The fluorescence of the super-
natants was measured at an emission wavelength of 562 nm and 
an excitation wavelength of 342 nm. The NEP activity was calcu-
lated as a difference in fluorescence between samples incubated 
with and without phosphoramidon, and expressed as relative flu-
orescence units.
 Statistical Analysis 
 The data were analyzed using SPSS 14.0 (SPSS Inc., Chicago, 
Ill., USA). Differences between the means were assessed by Stu-
dent’s t test or 1-way ANOVA followed by Fisher’s LSD or Tukey’s 
post-hoc tests. Correlation studies were performed by parametric 
correlation and linear regression analysis. The null hypothesis 
was rejected at the 0.05 level.
 Results 
 Absence of RAGE Reduced the Amount of Insoluble 
A  in 6-Month-Old ArcA  Mice 
 In order to evaluate the influence of  RAGE deletion 
(online suppl. fig. 1) on A  deposition, we examined the 
A  peptide levels in the brain regions relevant to cogni-
tion, i.e. the hippocampus and cortex. The A  levels were 
assessed with respect to the extraction conditions and the 
variant length (A  40 and A  42) using Western blot and 
C-terminus-specific ELISA. The brains were extracted 
sequentially in 1% Triton X-100, 2% SDS and 70% FA, to 
allow for the isolation of A  species that differ in the ag-
gregation state and cellular/extracellular localization, 
with SDS-extractable A  pertaining to the membrane-
enriched fraction and FA-extractable (insoluble) A  rep-
resenting extracellular amyloid. Both the Western blot 
and ELISA approaches indicated significantly lower over-
all levels of accumulated A  in the cortex and hippocam-
pus at the age of 6 months in RAGE –/– /arcA  animals 
compared to arcA  mice with normal RAGE expression. 
Interestingly, the difference was due to the low A  levels 
extracted into SDS and FA, but not caused by Triton X-
100-requiring peptide ( tables 1 and  2 ). Despite the clear 
differences in the amount of extractable A  found by bio-
chemical methods, histological analysis did not reveal 
any difference in A  -occupied brain areas at 6 months 
( fig. 1 a), possibly due to the fact that at this age, visible 
plaque formation has not yet started in arcA  mice  [2] . 
At the age of 12 months, when A  deposition has pro-
gressed much more, biochemical and histopathological 
approaches revealed no more difference in the total A  
load, nor A  40 and A  42 variants, in any of the fractions 
between RAGE –/– /arcA  and arcA  mice ( tables 1 and  2 ; 
 fig. 1 b). However, the A  40 level was significantly de-
creased in the serum of RAGE –/– /arcA  animals.
 Given the possibility that the genetic manipulation 
might not only influence A  deposition and quantities 
but also morphological features of deposits, we examined 
both plaques and CAA but found no structural differ-
ences between RAGE –/– /arcA  and arcA  mice ( fig. 2 
and  3 ). Plaques in RAGE –/– /arcA  animals, detected at 12 
months ( fig. 3 a, g), had the same dense-core morphology 
as arcA  mice ( fig. 3 b, d, h, j) and were also accompanied 
by severe CAA ( fig. 3 c, i).
 RAGE Did Not Influence APP Expression and 
Processing 
 To determine whether the decreased amount of A  
could be due to altered APP expression or processing 
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caused by the absence of RAGE, we examined the levels 
of full-length APP (APP), soluble APP (sAPP) as well as 
C-terminal fragments produced by   -secretase (CTF-  ) 
by Western blot using 6E10, 22C11 and anti-APP C-ter-
minal antibodies. There was no difference in APP, sAPP 
and CTF-  levels according to the densitometric analysis 
of immunoblots upon normalization to   -tubulin in the 
cortex and the hippocampus between the 2 transgenic 
groups ( fig. 4 ).
 RAGE –/– /ArcA  Mice Showed Increased
A  -Degrading Enzymatic Activity 
 Our finding that the cerebral levels of SDS- and FA-
soluble A  were reduced in the brains of 6-month-old 
mice without any change in APP processing suggested 
that the activity of 1 or more A  -degrading proteases 
might be increased. To test this hypothesis, we examined 
the enzymatic activity of 3 proteases in the cortices of 6- 
and 12-month-old animals. Analysis of IDE activity re-
vealed significant main effects of the APP transgene 
[F(1,16) = 28.218, p = 0.001] and of the RAGE knockout 
condition [F(1,16) = 37.102, p  ! 0.001], with no interac-
tion, indicating their additive effect. At the age of 6 
months, IDE in RAGE –/– /arcA  had a significantly high-
er activity than in arcA  mice (p = 0.05), RAGE –/– mice 
(p = 0.11) and wild-type animals (p  ! 0.001;  fig. 5 a). How-
ever, at the age of 12 months the difference between 
RAGE –/– /arcA  and arcA  was not statistically signifi-
cant; RAGE –/– /arcA  animals had an increased activity 
of the enzyme only in comparison with the wild-type an-
imals (p = 0.043). There was no significant difference in 
the activity of 2 other A  -degrading enzymes, ACE and 
neprilysin, among the 4 groups ( fig. 5 b, c).
 Absence of RAGE Did Not Ameliorate Cognitive 
Impairment 
 To clarify whether the reduced amount of A  in 
RAGE –/– /arcA  mice at 6 months would result in less se-
Table 1. A levels measured by ELISA specific for Ax-40 and Ax-42
Age 
months
Genotype A Cortex Hippocampus Serum
pg/ml1% Triton
ng/ml
2% SDS
ng/ml
70% FA
ng/ml
1% Triton, 
2% SDS, ng/ml
70% FA
ng/ml
6 RAGE–/–/arcA A40 4.5280.02 4.6280.09 1.5980.48* 3.4780.13 ND ND
A42 6.3780.10 4.5980.13* 1.3080.50* 2.2480.04 ND ND
arcA A40 4.6180.03 6.0280.62 11.3483.53 3.5680.21 ND ND
A42 6.6880.15 6.8880.87 6.5282.02 1.7680.33 ND ND
12 RAGE–/–/arcA A40 27.7388.93 143.48841.50 380.488111.04 20.3884.33 65.18818.37 258.51832.12*
A42 5.9281.07 50.1486.49 101.47842.07 5.5680.65 25.2785.35 ND
arcA A40 15.7188.83 62.41812.58 402.398140.74 11.8082.88 96.35833.93 432.70859.93
A42 4.0181.19 44.3885.90 97.64833.33 5.2980.92 36.13810.80 ND
Values are means 8 SE. ND = Not detectable. * p < 0.05. 
Table 2. Monomeric A levels determined by densitometric analysis of Western blot assay with 6E10 antibody
Age
months
Genotype Cortex Hippocampus
1% Triton 2% SDS 70% FA 1% Triton, 2% SDS 70% FA
6 RAGE–/–/arcA 96.0832.5 10.383.7** 7.783.9*** 67.0823.2 3.3681.8*
arcA 100.086.5 100.0835.0 100.0823.1 100.0830.1 100.0855.3
12 RAGE–/–/arcA 222.1888.8 164.7848.6 101.6824.7 76.2818.9 83.6825.7
arcA 100.0833.0 100.0812.4 100.0818.3 100.0815.7 100.0820.5
Data are mean relative intensity 8 SE. * p < 0.05; ** p <0.01; *** p < 0.001.
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vere cognitive deficits that had previously been described 
in arcA  mice, the different genotype groups were tested 
in the Y maze, a working memory test. There was no sig-
nificant difference in Y maze performance between the 
RAGE –/– /arcA  and arcA  animal groups at the age of 6 
and 12 months. Although they had less SDS- and FA-
soluble A  load at 6 months, the RAGE –/– /arcA  mice 
had the same extent of cognitive deficits as the arcA  
animals. This impairment was not due to the lack of 
RAGE, since the RAGE –/–  mice performed equally well as 
the wild-type animals ( fig. 6 ).
 Cognitive Impairment Correlated with
Triton-X-Extractable A  
 Given the cognitive deficits in the animals harboring 
the APP transgene, we evaluated whether the extent of ac-
cumulated A  was related to the degree of cognitive per-
formance in individual mice. There was a significant nega-
tive correlation between the percent alternation in the Y 
maze and monomeric A  cortical levels present in 1% Tri-
ton X-100 fraction determined by densitometric analysis of 
Western blot with 6E10 antibody but not with the A  levels 
in other fractions or in the hippocampus. Additionally, 
there was no significant correlation between Y-maze per-
formance and the levels of 2 length variants, A  40 or A  42. 
The association between soluble A  load in the cortical 
area and working memory impairment was significant at 
the age of 6 months for both RAGE –/– /arcA  (p = 0.0146) 
and arcA  mice (p = 0.043) ( fig. 7 a), and the r values ob-
tained for the 2 groups were not significantly different. At 
12 months of age, the negative correlation was only sig-
nificant for the RAGE –/– / arcA  mice (p = 0.020;  fig. 7 b).
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 Fig. 1. Percentage of brain areas occupied 
by A  deposits, detected by thioflavin S 
(ThioS) and 6E10 staining, at the age of 6 
( a ) and 12 ( b ) months. There was no statis-
tically significant difference between the 2 
APP transgene-bearing groups.  a  No thio-
flavin-S-positive deposits were detected in 
the hippocampus at the age of 6 months. 
Values are means  8 SE, n = 8–9 mice per 
group. CTX = Cortex; HIPP = hippocam-
pus. 
a b
dc
 Fig. 2. The lack of RAGE does not change 
A  deposition at the age of 6 months. In 
the overview of cortical sections of 6-
month-old RAGE –/– /arcA  ( a ) and arcA  
( b ) mice there were no plaques or CAA de-
tected, just a few 6E10-stained (green) A  
deposits that started to attract microglia 
(Iba1; red), as visible in ( c ) and ( d ) with en-
larged details from the overview images. 
Scale bar: 100   m ( a ,  b ); 50   m ( c ,  d ). 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 8
:5
6:
24
 A
M
 RAGE Does Not Affect Amyloid 
Pathology in Transgenic ArcA  Mice  
Neurodegenerative Dis 2009;6:270–280 275
a b
c d
e f
g h
i j
 Fig. 3. Plaque dense-core morphology and 
CAA at 12 months in the cortex and hip-
pocampus of RAGE –/– /arcA  ( a ,  c ,  e ,  g ,  i ) 
and arcA  ( b ,  d ,  f ,  h ,  j ).  a–d 6E10 staining 
(green), paralleled with the Iba1 staining 
of microglia [31], revealing plaque mor-
phology ( a ,  b ) and CAA ( c ,  d ).  e–j Thiofla-
vin-S-stained overview images of mouse 
cortices ( e ,  f ) and their respective enlarged 
details demonstrating dense-core plaques 
( g ,  h ) and CAA ( i ,  j ). Scale bar: 100   m ( e , 
 f ); 50   m ( a–d ,  g–j ). 
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 Fig. 4. Western-blot-based characterization of APP, sAPP  and 
CTFs in 6- and 12-month-old RAGE –/– /arcA  mice.  a Represen-
tative 6E10 immunoblot from 1% Triton X-100 cerebral cortex ho-
mogenates from 6-month-old animals.  b Densitometric analysis 
of APP, sAPP and CTF-  signal intensities in 6E10, 22C11 and 
APP C-terminal immunoblots, respectively, normalized to   -tu-
bulin. Each value represents the mean  8 SE of 8–9 six-month-old 
mice for each brain region analyzed. CTX = Cortex; HIPP = hip-
pocampus; wt = wild type. 
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 Fig. 5. Enzyme activity measurements in crude cortical homoge-
nates.  a  IDE activity was significantly increased in the RAGE –/– /
arcA  cortices at the age of 6 months in comparison with the 3 
other genotypes.  b There was no difference in ACE activity among 
the animal groups.  c No difference was detected in neprilysin ac-
tivity among the different genotypes. Values are means  8 SE,
n = 8–9 mice per group.  * p  ! 0.05;  * * p  ! 0.01;  * * * p  ! 0.001: 1-way 
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 Fig. 6. Behavioral performance in the Y 
maze, a working memory test measuring 
spontaneous alternation behavior, at the 
age of 6 ( a ) and 12 ( b ) months. RAGE –/– /
arcA  had impaired working memory in 
comparison to control animals already at 
the age of 6 months. Values are means  8 
SE, n = 8–9 mice per group.  * p  ! 0.05;
 * * p  ! 0.01: 1-way ANOVA followed by 
Fisher’s LSD post-hoc analysis. wt = Wild 
type. 
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 Lack of RAGE Did Not Alter the Amount of Microglia 
 No difference in the microglia-occupied brain area or 
microglial morphology was observed in RAGE –/– mice
in comparison to wild-type animals at both examined 
ages ( fig. 8 c, d). Also, these animals did not differ from 
RAGE –/– /arcA  and arcA  mice with respect to the mi-
croglia-occupied brain area at the age of 6 months, when 
no dense-core plaques or CAA can be demonstrated yet 
( fig. 8 a). At 12 months, there was a significant equal in-
crease in Iba1-occupied brain area in both RAGE –/–
 / arcA  and arcA  mice when compared to APP non-
transgenic animals ( fig. 8 b), due to the formation of 
plaques and CAA that attract microglia ( fig. 4 a–d).
 Discussion 
 Several lines of evidence suggested a role of the RAGE 
receptor in AD pathogenesis with different underlying 
processes proposed. Studies in mice and cell culture in-
dicated that RAGE promotes A  accumulation through 
2 different mechanisms. First, RAGE is thought to medi-
ate A  peptide influx into the central nervous system 
through the blood-brain barrier  [7, 8] , thus increasing the 
amount of A  in the brain. The second mechanism lead-
ing to enhanced A  accumulation via RAGE proposes a 
direct stimulation of BACE1 expression, the secretase in-
volved in A  production  [9] . In addition, RAGE is as-
sumed to promote AD pathology by activating microglia, 
with subsequent induction of chemotaxis, cell prolifera-
tion, as well as ROS and cytokine production  [1, 10, 11] . 
To better understand the in vivo role of RAGE in AD pa-
thology, we generated and characterized arcA  mice 
lacking RAGE. These animals had an increased IDE ac-
tivity during the first 6 months of life and were protected 
from A  accumulation only to a certain extent. There 
were lower levels of A  extractable by SDS and FA (in-
soluble A  ) in the brains of RAGE –/– /arcA  mice at the 
age of 6 months, but this effect disappeared by the age of 
12 months, most probably due to the constant peptide 
production overwhelming the clearance process. In addi-
tion, the observed IDE upregulation resulted from an ad-
ditive effect of  RAGE deletion and the APP transgene or 
probably A  accumulation, as previously suggested  [12, 
13] . Although it presumably decreased initial A  build-
up, the IDE-mediated clearance process did not prevent 
cognitive decline and eventually became inefficient at the 
age of 12 months given the similar amounts of cerebral 
A  in both genotypes. ArcA  mice have been previously 
shown to generate A  only in the nervous system  [2] , thus 
precluding the relevance of external A  influx into the 
brain to the development of brain pathology in this mouse 
model. In addition, our study showed significantly lower 
serum levels of A  40 in RAGE –/– /arcA  mice than in the 
arcA  animals at the age of 12 months, contradicting the 
possible relevance of A  transport across the blood-brain 
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 Fig. 7. Inverse correlation between Y maze performance and A  
cortical levels present in 1% Triton X-100 fraction determined by 
densitometric analysis of 6E10 immunoblot.  a  At 6 months, the 
levels of soluble monomeric A  in the cortical fraction were sig-
nificantly negatively correlated with the percent alternation in the 
Y maze in both RAGE –/– /arcA  (p = 0.0146) and arcA  mice (p = 
0.043).  b At 12 months of age the negative correlation was sig-
nificant only for the RAGE –/– /arcA  mice (p = 0.020). 
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barrier for cerebral A  accumulation. RAGE involve-
ment in APP processing via BACE did not seem to be 
plausible in the arcA  mice either given the identical lev-
els of CTF-  observed in both genotypes. Similarly, our 
study did not reveal any change in microglia number or 
morphology in animals lacking RAGE. The RAGE –/– /
arcA  mice had comparable brain areas occupied by mi-
croglia in both age groups. Additionally, there was a 
marked activation of microglia evident in parallel with 
the onset of fibrillar plaques in both genotypes, which 
would not favor an in vivo role of RAGE to promote mi-
croglia activation in AD either. This is in agreement with 
the previous findings in APP23 mice, whereby the major-
ity of activated microglia, present in the vicinity of amy-
loid plaques, did not upregulate RAGE expression  [14] .
 Differences observed between previous studies and 
the results presented here may be explained by confound-
ing factors not accounted for in previously applied ex-
perimental settings, methodologies and animal models. 
These include APP transgenic mice overexpressing RAGE 
or bearing dominant-negative RAGE (DN-RAGE), DN-
RAGE and wild-type mice injected or infused with A  , 
as well as APP transgenic or A  -infused mice which were 
treated with truncated, soluble form of RAGE, sRAGE  [7, 
15, 16] . Remarkably, sRAGE-treated animals show great-
er protection compared to RAGE-null (RAGE –/– ) ani-
mals against deleterious effects of inflammation  [17] , di-
abetic nephropathy and concomitant VEGF expression 
 [18] , or diabetic neuropathy  [19] , conditions in which 
RAGE is suggested to be a key pathology-mediating mol-
ecule. In addition, exogenous sRAGE blocks inflamma-
tion even in RAGE –/– animals  [17] , which altogether sug-
gests involvement of sRAGE in additional pathways 
linked to inflammatory response. Endogenous sRAGE is 
 Fig. 8. Percentage of brain areas occupied by microglia (Iba1+ 
cells) at the age of 6 ( a ) and 12 ( b ) months. The significant increase 
in both RAGE –/– /arcA  mice and arcA  observed at 12 months 
of age was associated with the plaque accumulation. Values are 
means  8 SE, n = 8–9 mice per group. There was no difference in 
the microglia-occupied brain area or microglial morphology be-
tween RAGE –/– (12 months;  c ) and wt (12 months;  d ) animals. 
Scale bar: 30   m. CTX = Cortex; HIPP = hippocampus; wt = wild 
type.  * p  ! 0.01,  * * p  ! 0.001: 1-way ANOVA followed by Tukey’s 
post-hoc analysis. 
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